Chronic liver disease (CLD) is increasing in prevalence worldwide. CLD has significant associated morbidity and mortality, including a negative impact on health-related quality of life (HRQOL), progression to cirrhosis, development of hepatocellular carcinoma (HCC), and need for liver transplantation. CLD disproportionately impacts racial, ethnic, sexual, and gender minorities. CLD is also more prevalent in populations experiencing challenging social determinants of health (SDOH) factors. Health disparities are prevalent across various forms of CLD, reflected in higher disease prevalence and severity, premature or excess adverse clinical outcomes and worse patient-reported outcomes. In this review, we highlight current epidemiology and health disparities across major forms of CLD, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), viral hepatitis, and autoimmune liver disease. Herein we discuss challenges with respect to disparities in screening, diagnosis, noninvasive testing for risk stratification, treatment, and rates of clinical outcomes. We outline actionable interventions from a broad public health level to the individual patient level with the goal of moving towards health equity. Lastly, we highlight areas in need of future research that can inform future interventions to achieve health equity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MCG.0000000000002169 | DOI Listing |
AIDS
March 2025
National Center for Epidemiology, Carlos III Health Institute.
Objective: We assessed the association between early HIV medical care interruption (MCI) and the development of AIDS-defining events (ADEs), serious non-AIDS events (SNAEs), and death among people with HIV (PWH) from the CoRIS cohort.
Design: We included antiretroviral-naive individuals aged at least 18 years at enrollment, recruited between 1 January 2004 and 30 May 2021, and followed-up until 30 November 2023.
Methods: Early MCI was defined as a time interval over 15 months between two consecutive visits, where the first of these visits occurred within the first 15 months of enrollment.
J Vet Intern Med
March 2025
Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
Introduction: Some massive or nodular liver tumors can make surgical resection dangerous. Transarterial embolization and chemoembolization recently have been evaluated in dogs and cats, but multinodular or diffuse tumors make selective embolization difficult, impractical, and may require multiple anesthetic events. Hepatic dearterialization in humans has been shown to be safe and sometimes successful in promoting temporary tumor regression.
View Article and Find Full Text PDFLiver Int
April 2025
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. MASLD is a multisystem disease where metabolic dysfunction plays a key role in the development of MASLD and its most relevant liver-related morbidities and extrahepatic complications, such as cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers. Among the least examined MASLD-related extrahepatic complications, an ever-increasing number of observational studies have reported a positive association between MASLD and the risk of serious bacterial infections (SBI) requiring hospital admission.
View Article and Find Full Text PDFCells
March 2025
School of Clinical Medicine, Tsinghua University, Beijing 100190, China.
Sepsis is a complex clinical syndrome closely associated with the occurrence of acute organ dysfunction and is often characterized by high mortality. Due to the rapid progression of sepsis, early diagnosis and intervention are crucial. Recent research has focused on exploring the pathological response involved in the process of sepsis.
View Article and Find Full Text PDFCells
March 2025
Immuno-Inflammation Laboratory, National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi 110067, India.
Hepatic lipogenesis combined with elevated endoplasmic reticulum (ER) stress is central to non-alcoholic steatohepatitis (NASH). However, the therapeutic targeting of key molecules is considerably less accomplished. Adeno-associated virus (AAV)-mediated gene therapies offer a new solution for various human ailments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!